Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management.

Sakti CjakrabartiHeidi D FinnesAmit Mahipal

Published in: Expert opinion on drug metabolism & toxicology (2022)

The development of FGFR inhibitors is a significant advancement in the therapeutic paradigm of advanced CCA. Ongoing research utilizing FGFR inhibitors in treatment-naïve patients, elucidation of resistance mechanisms to harness future trials, and exploration of combination strategies will transform the treatment landscape of CCA.

Keyphrases

current status
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
oxidative stress
peritoneal dialysis
prognostic factors
patient reported outcomes
smoking cessation